| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Internal Medicine [E. A. P., K. J. M., S. D. G., S. D. M.], Comprehensive Cancer Center [E. A. P., K. J. M., S. D. M.], and Bioethics Program University of Michigan Health System [S. D. G.], Ann Arbor, Michigan 48109, and Spectrum Health System, Grand Rapids, Michigan 49503 [K. E. L.]
The discovery of the breast cancer genes BRCA1 and BRCA2 has afforded those who seek breast and ovarian cancer risk counseling the option of genetic testing. Concerns about cost, confidentiality, and the potential for discrimination, however, may prevent some women from pursuing genetic testing. To determine the impact of these concerns on BRCA testing, we studied a cohort of 384 patients presenting de novo to a Breast and Ovarian Cancer Risk Evaluation Program, between January 6, 1997 and March 13, 2000. Of the 184 individuals who were themselves primary candidates for testing, 106 (58%) underwent BRCA1/2 sequencing. Of the 78 eligible patients who declined testing, 48 cited concerns about cost and insurance discrimination as their reason. On the basis of the number of positive results ascertained in the tested group, we estimate that approximately half of patients declining testing because of insurance coverage concerns would be positive for a BRCA mutation. We were unable to document any experiences of test result-based discrimination, although there were other negative insurance-related experiences. We conclude that in a high prior-risk clinic population, approximately one-quarter of patients eligible for BRCA testing may decline because of concerns about cost, confidentiality, and discrimination. Our research provides evidence that these fears may be discrepant with the actual experiences of patients in high-risk clinics.
This article has been cited by other articles:
|
|
 |
|
  S. L. Manne, D. C. Chung, D. S. Weinberg, H. S. Vig, Z. Catts, M. K. Cabral, K. Shannon, and N. J. Meropol Knowledge and Attitudes about Microsatellite Instability Testing among High-Risk Individuals Diagnosed with Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2110 - 2117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Ropka, J. Wenzel, E. K. Phillips, M. Siadaty, and J. T. Philbrick Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 840 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wang, D. J. Bowen, and S. L. R. Kardia Research and Practice Opportunities at the Intersection of Health Education, Health Behavior, and Genomics Health Educ Behav, October 1, 2005; 32(5): 686 - 701. [Abstract] [PDF]
|
|
|
|
|
|
O. I. Oloparde Genetics in Clinical Cancer Care: A Promise Unfulfilled among Minority Populations Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1683 - 1686. [Full Text] [PDF]
|
|
|
|
 |
|
 J Balmana, E M Stoffel, K M Emmons, J E Garber, and S Syngal Comparison of motivations and concerns for genetic testing in hereditary colorectal and breast cancer syndromes J. Med. Genet., April 1, 2004; 41(4): e44 - e44. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gray and O. I. Olopade Direct-to-Consumer Marketing of Genetic Tests for Cancer: Buyer Beware J. Clin. Oncol., September 1, 2003; 21(17): 3191 - 3193. [Full Text] [PDF]
|
|
|
|
|
|
H. T. Lynch, C. L. Snyder, J. F. Lynch, B. D. Riley, and W. S. Rubinstein Hereditary Breast-Ovarian Cancer at the Bedside: Role of the Medical Oncologist J. Clin. Oncol., February 15, 2003; 21(4): 740 - 753. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
